Form 4: Amylyx Pharmaceuticals Co-CEO Justin Klee Sells Shares to Cover Tax Obligations

Amylyx Pharmaceuticals' Co-CEO, Justin B. Klee, sold shares of common stock on March 31, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On March 31, 2025, Justin B. Klee, Co-Chief Executive Officer of Amylyx Pharmaceuticals, sold 21,490 shares of common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $3.4646, with individual transactions ranging from $3.44 to $3.58.
• Following the transaction, Klee directly owns 3,355,276 shares of Amylyx Pharmaceuticals' common stock.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (sale of shares to cover taxes) and doesn't inherently indicate positive or negative sentiment. It's a neutral event.

Industry Context

Form 4 filings are a routine part of insider trading activity and are required by the SEC to provide transparency into the transactions of company insiders. This sale appears to be related to tax obligations, which is a common reason for such transactions.

Stakeholder Impact

• The sale of shares by a company executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact as it is for tax purposes.

Key Dates

Keywords

Amylyx Pharmaceuticals, Justin B. Klee, Form 4, Share Sale, Tax Withholding, Restricted Stock Units, AMLX, Co-CEO